This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

CROMSOURCE Upgrades To The New Oracle Clinical Release 4.6.4

VERONA, Italy, January 29, 2013 /PRNewswire/ --

CROMSOURCE, a high quality ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions, today announced successful completion of a project to upgrade their data management system to the new Oracle Clinical Release 4.6.4 (replacing version 4.5.3.).

'Over the past 15 years, the Biometrics group within CROMSOURCE has conducted hundreds of important projects either as part of full-service agreements or as stand-alone assignments across all segments of the healthcare research sector, including medical devices, pharmaceuticals, biotechnologies and vaccines,' noted Hugo Hartmans, Director of Biometrics. 'We consistently delight our clients by delivering high quality services and proactively searching for the most efficient solution. As part of this commitment to satisfy our clients' needs, evidenced by our 80% repeat business level, CROMSOURCE decided to invest in upgrading to the latest Oracle Clinical Release.'

Key benefits of the upgrade include availability of web-based randomisation, provision of email alerts on entry of certain defined data (e.g. SAEs), increased flexibility of eCRF design and flow, conditional navigation and other increases in general usability. The combined effect of these changes is to increase the ease, speed and accuracy of data handling which in turn creates cleaner data, faster.

The upgraded version of Oracle Clinical and Remote Data Capture (RDC) is now installed and hosted on the state-of-the-art infrastructure in the CROMSOURCE European Headquarters, and is fully validated and maintained in accordance with all applicable international guidelines.

'This is an important milestone and reflects our commitment to remaining at the forefront of technological innovation and providing best in class solutions to our clients,' stated Oriana Zerbini MD, Chief Executive Officer of CROMSOURCE. 'CROMSOURCE has an enviable record of delivering high quality statistics and data management projects to our sponsors on time, on budget and to the highest quality. I am convinced that this development will create many added benefits for our clients.'

About CROMSOURCE: CROMSOURCE is a high quality ISO-certified international provider of outsourced services to the pharmaceutical, biotechnology and medical device industries, specialized in clinical development and staffing solutions. The CROMSOURCE Biometrics team is headquartered in Aachen, Germany, with another large group working from the CROMSOURCE office in Stirling in the UK. During the last 15 years the Biometrics group at CROMSOURCE has completed over 230 data management projects and over 50 EDC based studies.

Contact: Margherita Mosconi CROMSOURCE Phone: +39-045-8222811 Fax: +39-045-8222812

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $94.99 -0.02%
FB $99.54 -0.21%
GOOG $678.11 -0.68%
TSLA $148.25 0.18%
YHOO $26.82 -0.85%


Chart of I:DJI
DOW 16,014.38 -12.67 -0.08%
S&P 500 1,852.21 -1.23 -0.07%
NASDAQ 4,268.7630 -14.99 -0.35%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs